Lornoxicam
ApprovedSmall molecule
Lornoxicam is one of 137 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.
6
Indications
11
Total Trials
0
Active Trials
136
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Lornoxicam
PPOZEN
Approved
Ilaris
NovartisPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Bayer Aspirin
BayerPreclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Enbrel
IImmunex
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Glucophage
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Post Operative Pain1 trial
Inguinal hernia1 trial
Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair
Unknown status·—·Phase 3·NCT01069055·60 enrolled
6 more indications
Osteoarthritis1 trial
Total Knee Arthroplasty1 trial
Acute Coronary Syndrome1 trial
Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome
Completed·—·Phase 4·NCT00997750·85 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lornoxicam. EMBL-EBI & Wellcome Sanger Institute.
- [4]